← Back to Search

Epigenetic Modifiers

Dasatinib plus Quercetin for Aging

Phase 2
Waitlist Available
Led By Edwin Lee, MD
Research Sponsored by TruDiagnostic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to 6 months
Awards & highlights

Study Summary

This study is evaluating whether a drug called Quercitin and a drug called Dasatinib can slow down the aging process.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Epigenetic Age Test
Secondary outcome measures
Examining Methylation changes

Trial Design

1Treatment groups
Experimental Treatment
Group I: Quercetin and Dasatinib supplementsExperimental Treatment1 Intervention
500mg Quercetin and 50mg Dasatinib oral capsules on Monday, Tuesday, Wednesday (3 days in a row) per month for the duration of 6 months.

Find a Location

Who is running the clinical trial?

TruDiagnosticLead Sponsor
11 Previous Clinical Trials
461 Total Patients Enrolled
8 Trials studying Aging
351 Patients Enrolled for Aging
Edwin Lee, MDPrincipal InvestigatorThe Institute for Hormonal Balance

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Georgia
How old are they?
65+
What site did they apply to?
The Institute for Hormonal Balance
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I am a geroscience professor. I am very interested in potential geroprotectant properties of D + Q and would love to be involved.
PatientReceived 2+ prior treatments

What questions have other patients asked about this trial?

What is your treatment frequency protocol?
PatientReceived 1 prior treatment
Recent research and studies
EBioMedicineJournal
Senolytics Decrease Senescent Cells in Humans: Preliminary Report from a Clinical Trial of Dasatinib Plus Quercetin in Individuals with Diabetic Kidney Disease
Hickson, LaTonya J., Larissa G.P. Langhi Prata, Shane A. Bobart, Tamara K. Evans, Nino Giorgadze, Shahrukh K. Hashmi, Sandra M. Herrmann, et al.. 2019. “Senolytics Decrease Senescent Cells in Humans: Preliminary Report from a Clinical Trial of Dasatinib Plus Quercetin in Individuals with Diabetic Kidney Disease”. Ebiomedicine. Elsevier BV. doi:10.1016/j.ebiom.2019.08.069.
clinicaltrials.govStudy
Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging
2020. "Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04946383.
All > Dasatinib
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top